<DOC>
	<DOCNO>NCT02886715</DOCNO>
	<brief_summary>A Multi-Center , Double-Blind , Randomized , Vehicle-Controlled , Parallel-Group Study Comparing Tazarotene Cream 0.1 % TAZORAC® ( Tazarotene ) Cream 0.1 % Both Active Treatments Vehicle Control Treatment Acne Vulgaris</brief_summary>
	<brief_title>A Study Comparing Tazarotene Cream 0.1 % TAZORAC® ( Tazarotene ) Cream 0.1 % Both Placebo Control Treatment Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Healthy male nonpregnant female age ≥ 12 ≤ 40 year clinical diagnosis acne vulgaris . Must minimum ≥ 25 noninflammatory lesion ≥ 20 inflammatory lesion ≤ 2 nodulocystic lesion baseline face . Must definite clinical diagnosis acne vulgaris severity grade 2 , 3 , 4 per Investigator 's Global Assessment . Female subject pregnant , nurse plan become pregnant study participation . Have history hypersensitivity allergy tazarotene , retinoids and/or study medication ingredient . Presence skin condition would interfere diagnosis assessment acne vulgaris .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>